Braxia Scientific Corp launches KetaMD as first Florida patients complete initial virtual ketamine treatments at home

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) said it has successfully launched KetaMD in the US state of Florida, adding new patients and completing initial ketamine treatments.

Eligible patients, as determined by one of KetaMD’s licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their homes, according to Braxia.

KetaMD Inc, a wholly owned subsidiary of Braxia Scientific, is a telemedicine platform that provides access to safe and affordable at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder.

READ: Braxia Scientific posts 13% rise in Q1 revenue; launches KetaMD in US

According to Toronto, Ontario-based Braxia Scientific, in multiple studies, ketamine has been shown to have rapid and persistent benefits for acute care in suicidal patients who often suffer from mental health challenges. As National Suicide Awareness month kicks off in the US, KetaMD has ramped up operations and session availability to provide additional support to Florida residents in need of treatment.

Braxia Scientific CEO Dr. Roger McIntyre said the company is pleased to have treated its first patients through the KetaMD platform.

“KetaMD solves considerable issues by increasing access to innovative ketamine treatments for patients suffering from mental health disorders who don’t live close to a care provider, have difficulty accessing care, or are unable to go to the doctor because of circumstances like COVID-19 ,” said McIntyre in a statement.

KetaMD CEO Warren Gumpel said: “We started building the model for KetaMD more than five years ago with the goal of deploying the latest technology to improve people’s lives and to empower those living with depression and other mental health conditions to take steps necessary to seek and receive safe, high quality, affordable, reliable care. We are working on scaling KetaMD beyond Florida across the US, opening up the opportunity for people to receive care any time, from the comfort of their own homes.”

KetaMD is a Health Insurance Portability and Accountability Act-compliant telemedicine platform that provides at-home medical ketamine treatments prescribed by medical professionals and guided by registered nurses via a secure, online platform. Braxia said it aims to spread this treatment model across the US.

Briaxia Scientific’s wholly owned subsidiary, Braxia Health – formerly the Canadian Rapid Treatment Center of Excellence Inc – operates multidisciplinary community-based clinics in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.

Contact the author at [email protected]

Leave a Reply

Your email address will not be published.

Back to top button